

Concord thrives on fermentation services

09 June 2009 | News



Concord thrives on fermentation services

Using its expertise in the field of biotechnology and chemistry, Concord is concentrating on the fermentation-based products.



Gujarat-based Concord Biotech Limited (CBL) clocked annual revenue of Rs 97.10 crore for 2008-09 as against Rs 60 crore in fiscal 2007-08. It is an R&D-based biotechnology company having a state-of-the-art fermentation facility. It was acquired from DSM, a Dutch MNC, and commenced operations from 2000 with the manufacturing of Penicillin-G Amidase immobilized enzyme using its polymer matrix. In 2005, Matrix

Laboratories Limited announced its decision to acquire controlling stake in Concord Biotech. As per the term sheet executed, Matrix would acquire 55 percent stake in Concord Biotech.

Concord Biotech has a US FDA approved biotechnology facility with a client base that spreads across the globe including EU, US, Latin America, Korea, China, Middle East and many other parts of the world. Concord Biotech has a dedicated biotech and chemical synthesis R&D for development of biotechnology and down stream processing. Concord has built up eight dedicated biotech blocks for manufacturing statins, immunosuppressants, antibiotics and enzymes. Acquired by Sudhir Vaid, a biotechnologist with 29 years experience, from DSM.

Concord has diversified in the field of active pharmaceutical ingredients namely Lovastatin, Pravastatin, Simvastatin and Tacrolimus and has provided number of technologies on biotech products to many companies in Europe and India. Concord has received US FDA approval for its Lovastatin facilities and is striving to go for European Drug Master Files (EDMF). Concord Biotech offers fermentation services that rely on more than 30 years of experienced staff.

The company has the capacity and flexibility to ferment and develop processes for a variety of microbial organisms. Concord is the largest producer of Penicillin-G Amidase enzyme and is exporting this enzyme to a number of companies in China, Europe and the US besides having 90 percent market share in India. CBL is also producing and exporting Lovastatin and Tacrolimus to Europe and other countries. It is also starting the production of Simvastatin and Pravastatin in its newly US FDA approved facility in Gujarat. The company has put up a state-of-the-art manufacturing facility, which is located at

Ahmedabad, Gujarat, and is spread over about 28-acre of land for the production of hypolipemic agent Lovastatin, Pravastatin and Simvastatin. It has a dedicated facility for the production of Tacrolimus, an immunosuppressant. This apart, CBL has a well-equipped facility not only for the fermentation but also for the recovery and the powder processing areas. Concord has the largest shake flask capacity in India, where the wild strains can be manipulated by conventional mutation programs by a team of trained scientists. Concord undertakes the custom synthesis projects in biotechnology area too.